BruceYacyshynMDFRCPC AGAF FACG

PubMed

• 134 citations
  Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
  William J. Sandborn, Laurent Peyrin-Biroulet, Jinkun Zhang, Michael Chiorean, Severine Vermeire
  Gastroenterology. 2020-02-01
• 58 citations
  Fusobacterium nucleatum Adheres to Clostridioides difficile via the RadD Adhesin to Enhance Biofilm Formation in Intestinal Mucus
  Melinda A. Engevik, Heather A. Danhof, Jennifer M. Auchtung, Bradley T. Endres, Wenly Ruan
  Gastroenterology. 2021-03-01
• 31 citations
  CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.
  , Christopher Ma, Jurij Hanzel, Remo Panaccione, William J Sandborn
  Gastroenterology. 2022-10-01

Journal Articles

• Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection  
  Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves ..., N Engl J Med, 1/1/2017
• Pathophysiology of Clostridium difficile-Associated Diarrhea  
  Yacyshyn B., Gastroenterol Hepatol, 1/1/2016
• Importance of the evaluation of N-acetyltransferase enzyme activity prior to 5-aminosalicylic acid medication for ulcerative colitis" has been reviewed and accept...  
  Matthis A, Zhang B, Denson L, Yacyshyn B, Aihara E, Denson L, Montrose M., Inflamm Bowel Dis, 1/1/2016
• Epithelial Regeneration After Gastric Ulceration Causes Prolonged Cell-Type Alterations  
  Aihara E, Matthis AL, Karns RA, Engevik KA, Jiang P, Wang J, Yacyshyn BR, Montrose MH., Cell Mol Gastroenterol Hepatol., 1/1/2016
• Mo1670 Role for Differences in TLR Expression in the Clearance of Clostridium difficile Infections  
  Singh AD, Engevik KA, Yacyshyn MB, Yacyshyn BR., Gastroenterology, 1/1/2016
• The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]  
  Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colomb..., J Crohns Colitis, 1/1/2015
• Human Clostridium difficile infection: altered mucus production and composition  
  Engevik MA, Yacyshyn MB, Engevik KA, Wang J, Darien B, Hassett DJ, Yacyshyn BR, Worrell RT., Am J Physiol Gastrointest Liver Physiol, 1/1/2015
• Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile  
  Engevik MA, Engevik KA, Yacyshyn MB, Wang J, Hassett DJ, Darien B, Yacyshyn BR, Worrell RT., Am J Physiol Gastrointest Liver Physiol, 1/1/2015
•  
  Sarangdhar M, Yacyshyn MB, Aronow B, Yacyshyn BR., Gastroenterology, 1/1/2014
• Sa1276 Altered Mucus Oligosaccharide Composition in Human C difficile Infection  
  Engevik MA, Yacyshyn MB, Yacyshyn BR, Hassett DJ, Worrell RT, Gastroenterology, 1/1/2014
• High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis  
  Winter HS, Krzeski P, Heyman MB, Ibarguen-Secchia E, Iwanczak B, Kaczmarski M, Kierkus J, Kolacek S, Osuntokun B, Quiros JA, Shah M, Yacyshyn B, Dunnmon PM., J Pediatr Gastroenterol Nutr, 1/1/2014
• The role of gut inflammation in recurrent Clostridium difficile-associated disease  
  Yacyshyn MB, Yacyshyn BR., Clin Infect Dis., 1/1/2013
• 1028 Novel Proteomic Assessment for the Development of IBD in Active Duty US Military Personnel  
  Veerappan GR, Yacyshyn MB, Maydonovitch CL, Betteridge J, Wang F, Yacyshyn BR, Gastroenterology, 1/1/2013
• Su1281 Recognition That Angioectatic Lesions Use the TGF Beta Pathway Demonstrates a Novel Data-Based Model for Clinical Drug Development  
  Sarangdhar M, Kunnathur V, Aronow B, Yacyshyn B., Gastroenterology, 1/1/2013
• Tu1724 A Role for yIFN in Clostridium difficile Infection  
  Yacyshyn MB, Hollar A, Yacyshyn BR, Gastroenterology, 1/1/2013
• The Role of Gut Inflammation in Recurrent CDAD  
  Yacyshyn MB, Yacyshyn BR., Clinical Infectious Diseases., 1/1/2013
• Mo1114 The Balance of T Regulatory: TH17 Cells May Play a Role in Clostridium difficile Clearance  
  Yacyshyn MB, Hollar A, Wu J, Yacyshyn BR, Gastroenterology, 1/1/2012
• Mo1113 Clostridium difficile Surface Layer Protein (SLP) Elicits Differential Cytokine Responses in Initial and Recurrent Patients  
  Yacyshyn MB, Hollar A, Wu J, Su S, Yacyshyn BR, Gastroenterology, 1/1/2012
• Mo1682 Differential Success Predictors for Ulcerative Colitis Patients Treated With Mesalamine Using Proteomics  
  Yacyshyn BR, Wang F, Aronow B, Yacyshyn A, Yacyshyn MB., Gastroenterology, 1/1/2012
• Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)  
  Travis SPL, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, L�mann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn B, Ber..., GUT, 1/1/2012
• Proteomic prediction of clinical response for a large multicenter clinical trial of Ulcerative AQ2 Colitis  
  Yacyshyn BR, Wang F, Yacyshyn MB, Aronow B, Yacyshyn A., Inflammatory Bowel Diseases., 1/1/2011
• Evaluation of Goblet Cell Populations in HLA B27 Rats Before and After Treatment With the Soluble Fiber Carboxymethylcellulose  
  Yacyshyn MB, Case JW, Jin H, Yacyshyn BR., Gastroenterology, 1/1/2011
• Adhesion molecule therapeutics in IBD  
  Yacyshyn BR., Inflammatory Bowel Dis., 1/1/2008
• Delayed-release oral mesalamine 48 g/day (800 mg tablets) compared to 24 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: Th...  
  Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N., Can J Gastroenterol., 1/1/2007
• A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with a...  
  Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E, Clin Gastroenterol Hepatol., 1/1/2007
• Join now to see all

Books/Book Chapters

• Antisense therapeutics 
  Chapter: Antisense oligonucleotide treatment of inflammatory bowel diseases 
  Page 295.0 - 306.0Yacyshyn BREditors: M. Ian Phillips.Edition Seco,2004
• Seminars in Colon & Rectal Surgery 
  Chapter: Novel biological anti-inflammatory drugs for inflammatory bowel disease 
  Page 29.0 - 37.0Yacyshyn BREditors: D. Schoetz Jr..2001
• Advance Therapies of Inflammatory Bowel Disease 
  Chapter: Uses of novel manipulations of inflammatory mediator pathways 
  Page 165.0 - 169.0Yacyshyn BREditors: Bayless T, Hanauer S.Williams and Wilkins2001
• Immunosuppression in Inflammatory Bowel Diseases- Congress Short Report � Falk Symposium 
  Chapter: Future trends in molecular therapy: ICAM-1 antisense (ISIS 2302) multicenter trial in steroid-dependent Crohn�s disease. 
  Yacyshyn BR.Editors: Fellermann K.2000
• Standards, New Developments, Future Trends � Falk Symposium 
  Chapter: Development of antisense to intercellular adhesion molecule-1 (ISIS 2302) for inflammatory bowel disease therapy Immunosuppression in Inflammatory Bowel Diseases 
  Page 179.0 - 184.0Yacyshyn BR.Editors: Fellermann K, Jewell DP, Sandborn WJ, Scholmerich J, Strange EF.2000
• Adhesion Molecules 
  Chapter: The role of adhesion molecules in the gastrointestinal tract 
  Yacyshyn BR and Wallace JL.Landes Publications Inc.1998
• Join now to see all

Abstracts/Posters

• Clostridium difficile Toxins A and B Decrease SLC26A3 Protein Expression in Human Intestinal Epithelial Cells.
  Coffing H, Priyamvada S, Natarajan Anbazhagan A, Salibay C, Engevik M, Versalovic J, Yacyshyn MB, Yacyshyn B, Tyagi S, Saksena S, Gill R, Alrefai W, Dudeja P., American Journal of Physiology-Gastrointestinal and Liver Physiology, 1/1/2018
• Bezlotoxumab for prevention of recurrent C. difficile infection in patients at increased risk for recurrence
  Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, Ellison MC, Hanson ME, Guris D, Dorr MB., Clin Infect Dis., 1/1/2018
• Upadacitinib phase 2 study Celest.
  Yacyshyn BR, United European Gastroenterology Week, 1/1/2018
• A Randomized, Double-Blind, Placebo-Controlled Induction Trial of a Selective, Oral S1P Receptor Modulator, Etrasimod (APD334) in Moderate to Severe Ulcerative Colitis...
  United European Gastroenterology Week, 1/1/2018
• A Randomized, Double-Blind, Placebo-Controlled Induction Trial of a Selective, Oral S1P Receptor Modulator, Etrasimod (APD334) in Moderate to Severe Ulcerative Colitis...
  American College of Gastroenterology, 1/1/2018
• Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
  Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves ..., N Engl J Med, 1/1/2017
• Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridium difficile Infection: a phase 2, randomised, double-blind, active-controll...
  Vickers RJ, Tillotson GS, Nathan R, MD, Hazan S, Pullman J, Lucasti C, Deck K, Yacyshyn B, Maliakkal B, Pesant Y, Tejura B, Roblin D, Gerding DN, Wilcox MH, MD for the..., Lancet Infect Dis, 1/1/2017
• Efficacy of bezlotoxumab in patients with recurrent Clostridium difficile infection: pooled analysis of data from the MODIFY trials
  Yacyshyn BR, Digestive Disease Week (DDW), 1/1/2017
• Asymptomatic C. difficile Colonization: A Potential Source of Infection in an Inpatient Urban Hospital Service
  Alexander R. Drinnan, Bruce Yacyshyn, MD FACG, World Congress of Gastroenterology at ACG, 1/1/2017
• Asymptomatic C. difficile Colonization: Infection Rates in Inflammatory Bowel Disease by Treatment Class
  Andrei Jipa, BS, MS, Mary Beth Yacyshyn, PhD, Bruce Yacyshyn, MD, FACG, World Congress of Gastroenterology at ACG, 1/1/2017
• Metabolic profiling of human in-patient stools: The influence of C. difficile infection and recurrence
  Mary Beth Yacyshyn, PhD, Jessica Kukay, Lindsey Romick-Rosendale, PhD, Bruce Yacyshyn, MD, Infectious Diseases Society of America (IDSA), 1/1/2017
• Mo1670 Role for Differences in TLR Expression in the Clearance of Clostridium difficile Infections.
  Singh AD, Engevik KA, Yacyshyn MB, Yacyshyn BR, Gastroenterology, 1/1/2016
• Epithelial Regeneration After Gastric Ulceration Causes Prolonged Cell-Type Alterations
  Aihara E, Matthis AL, Karns RA, Engevik KA, Jiang P, Wang J, Yacyshyn BR, Montrose MH, Cell Mol Gastroenterol Hepatol., 1/1/2016
• Importance of the evaluation of N-acetyltransferase enzyme activity prior to 5-aminosalicylic acid medication for ulcerative colitis" has been reviewed and accept...
  Matthis A, Zhang B, Denson L, Yacyshyn B, Aihara E, Denson L, Montrose M., Inflamm Bowel Dis, 1/1/2016
• Pathophysiology of Clostridium difficile-Associated Diarrhea.
  Yacyshyn B, Gastroenterol Hepatol, 1/1/2016
• Ridinilazole for Clostridium difficile Infections: Safety and Efficacy Compared with Vancomycin from the CoDIFy Phase 2 Trial
  Yacyshyn BR, 1/1/2016
• Environmental Risk Factors Associated with Recurrent Clostridium difficile Infection
  Yacyshyn BR, ACG, 1/1/2016
• The Self-Management Transition Enhancement Program (STEP): Study Design and Preliminary Findings
  Yacyshyn BR, CCFA Advances, 1/1/2016
• Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile.
  Engevik MA, Engevik KA, Yacyshyn MB, Wang J, Hassett DJ, Darien B, Yacyshyn BR, Worrell RT., Am J Physiol Gastrointest Liver Physiol, 1/1/2015
• Human Clostridium difficile infection: altered mucus production and composition.
  Engevik MA, Yacyshyn MB, Engevik KA, Wang J, Darien B, Hassett DJ, Yacyshyn BR, Worrell RT, Am J Physiol Gastrointest Liver Physiol, 1/1/2015
• Mo1223 Lower Expression of PPARgamma in AVM Tissue Provides a Novel Therapeutic Target for Use of Glitazones in Treatment of GI Bleeding: Validation of Our Large-Scale...
  Sarangdhar M, Gruenzel A, Yacyshyn M, Aronow B, Yacyshyn BR, Gastroenterology, 1/1/2015
• The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS].
  Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colomb..., J Crohns Colitis, 1/1/2015
• Lower expression in PPARgamma in AVM tissue provides a novel therapeutic target for use of glitazones in treatment of GI bleeding: Validation of our large-scale clinic...
  Yacyshyn BR, DDW, Novel Diagnostics and Therapeutics in Intestinal Disease, 1/1/2015
• High- and Low-Dose Oral Delayed-Release Mesalamine in Children With Mild-to-Moderately Active Ulcerative Colitis.
  Winter HS, Krzeski P, Heyman MB, Ibarguen-Secchia E, Iwanczak B, Kaczmarski M, Kierkus J, Kolacek S, Osuntokun B, Quiros JA, Shah M, Yacyshyn B, Dunnmon PM., J Pediatr Gastroenterol Nutr, 1/1/2014
• Clostridium difficile recurrence is characterized by pro-inflammatory peripheral blood mononuclear cell (PBMC) phenotype.
  Yacyshyn MB, Reddy TN, Plageman LR, Wu J, Hollar AR, Yacyshyn BR., J Med Microbiol, 1/1/2014
• Join now to see all

Lectures

• Pathogenesis and Immunology of recurrent C. difficile infection 
  St. Vincent�s Hospital, Melbourne, Australia, 2015; Alfred Hospital, Monash University, Melbourne, A - 1/1/2015
• Treating Inflammatory Disease with Biosimilars: What Every GI Specialist Should Know 
  Honolulu, HI - 1/1/2015
• C. difficile for the Clinician 
  1/1/2015
• Treatment of Clostridium difficile infection: an update 
  Cincinnati, OH - 1/1/2014
• Foxp3+CD3- cells in Clostridium difficile infection (CDI) 
  Chicago, IL - 1/1/2014
• PPARgamma agonists in the treatment of angioectasia: Regulating the TGFbeta signaling pathway, angiogenesis and wound repair mechanisms 
  Chicago, IL - 1/1/2014
• Altered mucus oligosaccharide composition in human C. difficile infection 
  Chicago, IL - 1/1/2014
• IBD and Upper GI Disease 
  1/1/2013
• Diarrheal Illnesses - Crohn�s Disease 
  1/1/2013
• Influence of clinical history on scoring of the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) 
  Vienna, Austria - 1/1/2013
• Drug therapy for IBD 
  Cincinnati Children�s Hospital Medical Center, Cincinnati, Ohio - 1/1/2013
• Recognition that angioectatic lesions use the TGF beta pathway demonstrates a novel data-based model for clinical drug development 
  Orlando, Florida - 1/1/2013
• Novel Proteomic Assessment for the Development of IBD in Active Duty US Military Personnel 
  Orlando, Florida - 1/1/2013
• A role for Gamma IFN in Clostridium difficile Infection 
  Orlando, Florida - 1/1/2013
• Biomarker development, chemical biology and drug discovery 
  Central South University, Changsa, China - 1/1/2013
• Proteomics in IBD 
  Cincinnati Children�s Hospital Medical Center, Cincinnati, Ohio - 1/1/2012
• Bench to Bedside, 5-ASA 
  University of Cincinnati, Cincinnati, Ohio - 1/1/2012
• Proteomics in Inflammatory Bowel Disease Diagnosis 
  Central South University, Changsa, China - 1/1/2012
• Vaccine therapy for C. difficile 
  San Diego, CA - 1/1/2012
• Gamma IFN Production in Clostridium difficile Infection 
  Vancouver - 1/1/2011
• Gastroenterology 
  University of Kentucky, Clinical Research, Lexington, Kentucky - 1/1/2007
• Two phase 3 studies of Alicaforsen (ISIS-2302), an antisense oligonucleotide to human ICAM-1, in the treatment of moderate to severe Crohn�s disease 
  Chicago, Illinois - 1/1/2005
• Management of Upper Gastrointestinal Bleeding 
  Sandusky, Ohio - 1/1/2003
• Proton pump inhibitor update 
  Hillcrest Hospital, Cleveland, Ohio - 1/1/2003
• Making Sense of Antisense 
  Case Western Reserve University, Cleveland, Ohio - 1/1/2003
• Join now to see all

Other

• Clostridium difficile Toxins A and B Decrease SLC26A3 Protein Expression in Human Intestinal Epithelial Cells. 
  Coffing H, Priyamvada S, Natarajan Anbazhagan A, Salibay C, Engevik M, Versalovic J, Yacyshyn MB, Yacyshyn B, Tyagi S, Saksena S, Gill R, Alrefai W, Dudeja P
  1/1/2018
• Special Report: Management of Global Enteric Infections 
  Yacyshyn, BR., Gastroenterology and Endoscopy News
  1/1/2013
• Information on medications commonly used for people suffering from Crohn�s disease or ulcerative colitis. 
  Fedorak RN, Fisher D, Yacyshyn BR, Thomson ABR
  1/1/2001
• Antisense therapy for steroid refractory Crohn�s disease. 
  CFRN TV
  1/1/1996
• Reflux Esophagitis. 
  CAGS Course and Manual
  1/1/1989
• Antisense therapy for Crohn�s disease--reporting Phase II data. 
  CFRN TV, ITV, A Channel, CBC, Folio
  1/28/1997
• Crohn�s awareness 
  ITV
  1/4./1998
• C. difficile infection 
  Sirius Satelite Radio
  1/7./2010
• Join now to see all